| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Translocation, Genetic | 31 | 2016 | 363 | 2.510 |
Why?
|
| Chromosome Aberrations | 32 | 2022 | 628 | 1.810 |
Why?
|
| Salivary Gland Neoplasms | 11 | 2017 | 67 | 1.610 |
Why?
|
| Osteosarcoma | 12 | 2022 | 264 | 1.380 |
Why?
|
| Gene Amplification | 26 | 2015 | 247 | 1.290 |
Why?
|
| Tumor Suppressor Protein p53 | 11 | 2018 | 797 | 1.240 |
Why?
|
| Carcinoma, Adenoid Cystic | 8 | 2015 | 34 | 1.210 |
Why?
|
| Cell Cycle Proteins | 7 | 2011 | 709 | 1.120 |
Why?
|
| Nucleic Acid Hybridization | 28 | 2008 | 397 | 1.100 |
Why?
|
| Lymphoma, B-Cell | 12 | 2011 | 149 | 1.080 |
Why?
|
| In Situ Hybridization, Fluorescence | 38 | 2015 | 793 | 1.060 |
Why?
|
| Bone Neoplasms | 10 | 2022 | 447 | 1.050 |
Why?
|
| Karyotyping | 31 | 2017 | 324 | 1.020 |
Why?
|
| Chromosomes, Human, Pair 3 | 12 | 2016 | 100 | 0.940 |
Why?
|
| Aneuploidy | 7 | 2013 | 146 | 0.840 |
Why?
|
| Mammary Neoplasms, Experimental | 3 | 2013 | 246 | 0.840 |
Why?
|
| Chromosomes, Human, Pair 6 | 12 | 2011 | 145 | 0.800 |
Why?
|
| Oncogene Proteins, Fusion | 6 | 2022 | 236 | 0.750 |
Why?
|
| DNA, Neoplasm | 16 | 2013 | 320 | 0.720 |
Why?
|
| Gene Expression Regulation, Neoplastic | 20 | 2022 | 2137 | 0.710 |
Why?
|
| DNA-Binding Proteins | 15 | 2011 | 2178 | 0.710 |
Why?
|
| Carcinoma, Squamous Cell | 13 | 2007 | 872 | 0.660 |
Why?
|
| Adenocarcinoma | 8 | 2016 | 1071 | 0.640 |
Why?
|
| Endopeptidases | 2 | 2011 | 119 | 0.640 |
Why?
|
| Chromosome Mapping | 16 | 2013 | 1126 | 0.620 |
Why?
|
| Chromosomes, Human, Pair 14 | 12 | 2011 | 103 | 0.610 |
Why?
|
| Chromosomes, Human, Pair 12 | 6 | 2016 | 95 | 0.610 |
Why?
|
| Separase | 3 | 2013 | 29 | 0.590 |
Why?
|
| Transcription Activator-Like Effector Nucleases | 2 | 2018 | 3 | 0.580 |
Why?
|
| Chromosomes, Human, Pair 7 | 4 | 2016 | 78 | 0.570 |
Why?
|
| Human Embryonic Stem Cells | 2 | 2018 | 23 | 0.570 |
Why?
|
| Proto-Oncogene Proteins | 11 | 2015 | 625 | 0.560 |
Why?
|
| Nuclear Proteins | 8 | 2008 | 1351 | 0.540 |
Why?
|
| Chromosomes, Human, Pair 1 | 5 | 2016 | 152 | 0.540 |
Why?
|
| Chromosome Deletion | 13 | 2015 | 666 | 0.530 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 7 | 2009 | 151 | 0.530 |
Why?
|
| Gene Rearrangement | 9 | 2013 | 331 | 0.520 |
Why?
|
| Chromosomes, Human, Pair 9 | 5 | 2015 | 115 | 0.520 |
Why?
|
| Gene Dosage | 14 | 2015 | 458 | 0.500 |
Why?
|
| Cell Line, Tumor | 21 | 2022 | 3798 | 0.480 |
Why?
|
| Gene Editing | 2 | 2018 | 213 | 0.480 |
Why?
|
| Head and Neck Neoplasms | 9 | 2007 | 702 | 0.470 |
Why?
|
| Tumor Cells, Cultured | 19 | 2009 | 1107 | 0.460 |
Why?
|
| Parotid Neoplasms | 2 | 2016 | 17 | 0.440 |
Why?
|
| Transcription Factors | 12 | 2022 | 2738 | 0.440 |
Why?
|
| Chromosomes, Human, Pair 8 | 8 | 2015 | 82 | 0.430 |
Why?
|
| Ovarian Neoplasms | 7 | 2004 | 468 | 0.410 |
Why?
|
| NFI Transcription Factors | 2 | 2015 | 54 | 0.410 |
Why?
|
| Chromosomes, Human | 6 | 2009 | 137 | 0.400 |
Why?
|
| Humans | 124 | 2022 | 134156 | 0.400 |
Why?
|
| Biomarkers, Tumor | 7 | 2016 | 1721 | 0.400 |
Why?
|
| Cytogenetic Analysis | 6 | 2014 | 82 | 0.380 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2015 | 218 | 0.380 |
Why?
|
| Cell Transformation, Neoplastic | 8 | 2012 | 645 | 0.370 |
Why?
|
| RNA, Long Noncoding | 3 | 2022 | 250 | 0.370 |
Why?
|
| Multiple Myeloma | 4 | 2005 | 202 | 0.370 |
Why?
|
| Neoplasm Metastasis | 5 | 2015 | 746 | 0.370 |
Why?
|
| Mice | 29 | 2017 | 19055 | 0.370 |
Why?
|
| Transposases | 2 | 2013 | 45 | 0.370 |
Why?
|
| Homozygote | 3 | 2018 | 570 | 0.360 |
Why?
|
| Telomere | 3 | 2003 | 231 | 0.360 |
Why?
|
| Female | 74 | 2022 | 71928 | 0.360 |
Why?
|
| Cell Proliferation | 9 | 2022 | 2563 | 0.350 |
Why?
|
| Lymphoma, T-Cell | 1 | 2011 | 63 | 0.350 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 10 | 2015 | 1071 | 0.350 |
Why?
|
| Uterine Cervical Neoplasms | 5 | 2007 | 264 | 0.350 |
Why?
|
| Chromosome Banding | 13 | 2014 | 140 | 0.340 |
Why?
|
| Antigens, CD19 | 2 | 2013 | 181 | 0.340 |
Why?
|
| Comparative Genomic Hybridization | 4 | 2013 | 580 | 0.310 |
Why?
|
| Lymphoma, Non-Hodgkin | 5 | 2004 | 169 | 0.310 |
Why?
|
| Breast Neoplasms | 5 | 2014 | 2771 | 0.310 |
Why?
|
| Medulloblastoma | 3 | 2014 | 571 | 0.300 |
Why?
|
| Mutation | 11 | 2022 | 6338 | 0.300 |
Why?
|
| Phosphoprotein Phosphatases | 2 | 2011 | 127 | 0.300 |
Why?
|
| Carcinoma, Papillary | 4 | 2004 | 96 | 0.290 |
Why?
|
| Stem Cells | 2 | 2015 | 754 | 0.290 |
Why?
|
| Neoplastic Stem Cells | 3 | 2014 | 352 | 0.290 |
Why?
|
| RecQ Helicases | 1 | 2018 | 64 | 0.290 |
Why?
|
| Gene Fusion | 2 | 2016 | 61 | 0.290 |
Why?
|
| Male | 59 | 2019 | 66127 | 0.290 |
Why?
|
| Leukemia | 1 | 2011 | 379 | 0.290 |
Why?
|
| Gene Expression Profiling | 10 | 2015 | 1923 | 0.280 |
Why?
|
| Animals | 31 | 2017 | 36557 | 0.280 |
Why?
|
| Disease Progression | 4 | 2011 | 2266 | 0.280 |
Why?
|
| Multiprotein Complexes | 1 | 2008 | 219 | 0.280 |
Why?
|
| Phenotype | 7 | 2016 | 4598 | 0.270 |
Why?
|
| Blotting, Western | 5 | 2013 | 1140 | 0.270 |
Why?
|
| Longevity | 2 | 2011 | 160 | 0.270 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2008 | 207 | 0.270 |
Why?
|
| Trans-Activators | 3 | 2015 | 840 | 0.270 |
Why?
|
| Base Sequence | 13 | 2014 | 3180 | 0.270 |
Why?
|
| Zinc Finger Protein GLI1 | 2 | 2016 | 37 | 0.270 |
Why?
|
| Stomach Neoplasms | 4 | 2016 | 566 | 0.260 |
Why?
|
| Genes, p53 | 3 | 2015 | 234 | 0.260 |
Why?
|
| Chromosomes, Human, Pair 2 | 6 | 2006 | 123 | 0.260 |
Why?
|
| Salivary Ducts | 2 | 2017 | 4 | 0.250 |
Why?
|
| Chromosomes, Human, Pair 18 | 3 | 2011 | 64 | 0.250 |
Why?
|
| Sequence Deletion | 2 | 2008 | 539 | 0.250 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 10 | 2017 | 1332 | 0.250 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2018 | 232 | 0.250 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2011 | 146 | 0.250 |
Why?
|
| Neoplasm Proteins | 5 | 2014 | 719 | 0.250 |
Why?
|
| Chromosomal Instability | 3 | 2011 | 63 | 0.250 |
Why?
|
| Burkitt Lymphoma | 2 | 2022 | 141 | 0.250 |
Why?
|
| Sarcoma, Experimental | 1 | 2015 | 16 | 0.240 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2015 | 32 | 0.240 |
Why?
|
| Models, Biological | 2 | 2011 | 1539 | 0.240 |
Why?
|
| Polymerase Chain Reaction | 11 | 2008 | 1627 | 0.240 |
Why?
|
| Apoptosis | 9 | 2015 | 1946 | 0.230 |
Why?
|
| Tumor Suppressor Proteins | 4 | 2011 | 510 | 0.230 |
Why?
|
| Sarcoma, Ewing | 2 | 2013 | 116 | 0.230 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2015 | 169 | 0.230 |
Why?
|
| Ataxin-1 | 1 | 2015 | 162 | 0.230 |
Why?
|
| Leukemia, Myeloid | 2 | 2000 | 83 | 0.220 |
Why?
|
| Soft Tissue Neoplasms | 2 | 2013 | 128 | 0.220 |
Why?
|
| Receptor, Notch1 | 1 | 2014 | 80 | 0.220 |
Why?
|
| MAP Kinase Kinase Kinase 3 | 1 | 2014 | 9 | 0.220 |
Why?
|
| Genes, Tumor Suppressor | 6 | 2004 | 225 | 0.220 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2014 | 39 | 0.220 |
Why?
|
| Chromosomes, Human, Pair 20 | 3 | 2004 | 34 | 0.220 |
Why?
|
| Radiation, Ionizing | 1 | 2003 | 43 | 0.210 |
Why?
|
| Actins | 1 | 2016 | 353 | 0.210 |
Why?
|
| Metaphase | 4 | 2008 | 35 | 0.210 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2022 | 820 | 0.210 |
Why?
|
| Wnt Signaling Pathway | 1 | 2015 | 207 | 0.210 |
Why?
|
| Middle Aged | 31 | 2016 | 29399 | 0.210 |
Why?
|
| Thyroid Neoplasms | 4 | 2004 | 262 | 0.210 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2013 | 66 | 0.210 |
Why?
|
| Spectral Karyotyping | 4 | 2007 | 8 | 0.210 |
Why?
|
| Carcinoma | 3 | 2012 | 322 | 0.200 |
Why?
|
| Pseudouridine | 1 | 2003 | 3 | 0.200 |
Why?
|
| Aged | 28 | 2014 | 21775 | 0.200 |
Why?
|
| Chromosomes, Human, Pair 11 | 4 | 2013 | 90 | 0.200 |
Why?
|
| Testicular Neoplasms | 3 | 2002 | 135 | 0.200 |
Why?
|
| Dyskeratosis Congenita | 1 | 2003 | 19 | 0.200 |
Why?
|
| Immunohistochemistry | 6 | 2016 | 1765 | 0.200 |
Why?
|
| Tripartite Motif-Containing Protein 28 | 1 | 2022 | 16 | 0.200 |
Why?
|
| Mice, Inbred C57BL | 7 | 2015 | 4879 | 0.200 |
Why?
|
| RNA, Ribosomal | 1 | 2003 | 66 | 0.200 |
Why?
|
| Leukemia, Megakaryoblastic, Acute | 1 | 2022 | 19 | 0.200 |
Why?
|
| T-Lymphocytes | 2 | 2013 | 1812 | 0.200 |
Why?
|
| Oncogenes | 4 | 2013 | 181 | 0.190 |
Why?
|
| Adenoma, Pleomorphic | 1 | 2012 | 6 | 0.190 |
Why?
|
| Cell Lineage | 2 | 2015 | 370 | 0.190 |
Why?
|
| Rubinstein-Taybi Syndrome | 1 | 2022 | 17 | 0.190 |
Why?
|
| Mixed Tumor, Malignant | 2 | 2004 | 2 | 0.190 |
Why?
|
| Aged, 80 and over | 14 | 2014 | 7217 | 0.190 |
Why?
|
| Genes, myc | 4 | 2008 | 107 | 0.190 |
Why?
|
| Systems Biology | 1 | 2012 | 63 | 0.190 |
Why?
|
| Loss of Heterozygosity | 4 | 2009 | 135 | 0.190 |
Why?
|
| CD24 Antigen | 1 | 2011 | 32 | 0.190 |
Why?
|
| Chromosome Breakage | 7 | 2004 | 167 | 0.190 |
Why?
|
| Mediastinal Neoplasms | 1 | 2002 | 44 | 0.180 |
Why?
|
| Cloning, Molecular | 8 | 2006 | 912 | 0.180 |
Why?
|
| Mice, Transgenic | 4 | 2015 | 2539 | 0.180 |
Why?
|
| RNA-Binding Proteins | 3 | 2013 | 622 | 0.180 |
Why?
|
| Genome, Human | 6 | 2015 | 1351 | 0.180 |
Why?
|
| Radiation Tolerance | 2 | 2011 | 67 | 0.180 |
Why?
|
| T-Box Domain Proteins | 2 | 2015 | 127 | 0.180 |
Why?
|
| Genetic Variation | 3 | 2010 | 1631 | 0.170 |
Why?
|
| Polymorphism, Genetic | 3 | 2004 | 897 | 0.170 |
Why?
|
| Gene Deletion | 5 | 2015 | 811 | 0.170 |
Why?
|
| Proto-Oncogene Proteins c-myb | 1 | 2010 | 7 | 0.170 |
Why?
|
| Lung Neoplasms | 4 | 2012 | 1787 | 0.170 |
Why?
|
| Mitogen-Activated Protein Kinase Phosphatases | 1 | 2010 | 15 | 0.170 |
Why?
|
| Oncogene Fusion | 1 | 2010 | 26 | 0.170 |
Why?
|
| Dual-Specificity Phosphatases | 1 | 2010 | 24 | 0.170 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 3 | 2001 | 177 | 0.170 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2010 | 65 | 0.170 |
Why?
|
| Trisomy | 4 | 2014 | 112 | 0.170 |
Why?
|
| Mammary Glands, Animal | 1 | 2013 | 479 | 0.170 |
Why?
|
| Cerebellar Neoplasms | 1 | 2014 | 461 | 0.170 |
Why?
|
| Carcinoma, Ductal | 2 | 2014 | 9 | 0.170 |
Why?
|
| Cell Differentiation | 4 | 2015 | 2045 | 0.170 |
Why?
|
| Receptors, Antigen | 1 | 2010 | 34 | 0.170 |
Why?
|
| Carrier Proteins | 2 | 2015 | 1077 | 0.160 |
Why?
|
| Neoplasms, Plasma Cell | 1 | 2009 | 3 | 0.160 |
Why?
|
| Lymphoma, Large-Cell, Immunoblastic | 1 | 2009 | 5 | 0.160 |
Why?
|
| Hepatocytes | 1 | 2011 | 245 | 0.160 |
Why?
|
| Sarcoma, Myeloid | 1 | 2019 | 11 | 0.160 |
Why?
|
| DNA Mutational Analysis | 3 | 2002 | 843 | 0.160 |
Why?
|
| Myocardium | 1 | 2015 | 1046 | 0.160 |
Why?
|
| Myelodysplastic Syndromes | 2 | 2002 | 128 | 0.160 |
Why?
|
| Glioma | 1 | 2014 | 540 | 0.160 |
Why?
|
| Fibroblasts | 3 | 2014 | 928 | 0.160 |
Why?
|
| Lymphoma, Follicular | 2 | 2007 | 30 | 0.160 |
Why?
|
| Adult | 25 | 2018 | 31945 | 0.160 |
Why?
|
| Brain Neoplasms | 2 | 2014 | 1409 | 0.160 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 1999 | 43 | 0.150 |
Why?
|
| DNA Transposable Elements | 1 | 2010 | 189 | 0.150 |
Why?
|
| Nerve Sheath Neoplasms | 1 | 2009 | 24 | 0.150 |
Why?
|
| RNA, Messenger | 9 | 2014 | 2915 | 0.150 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2010 | 825 | 0.150 |
Why?
|
| ErbB Receptors | 1 | 2010 | 303 | 0.150 |
Why?
|
| Molecular Sequence Data | 11 | 2002 | 3980 | 0.150 |
Why?
|
| Protein Subunits | 4 | 2015 | 174 | 0.150 |
Why?
|
| Chromosome Painting | 6 | 2004 | 18 | 0.150 |
Why?
|
| Chromatids | 2 | 2008 | 41 | 0.150 |
Why?
|
| Chondroma | 1 | 2008 | 6 | 0.150 |
Why?
|
| Neurofibromatosis 1 | 1 | 2009 | 65 | 0.150 |
Why?
|
| Parathyroid Neoplasms | 1 | 1998 | 23 | 0.150 |
Why?
|
| Fibroma | 1 | 2008 | 31 | 0.140 |
Why?
|
| Myeloproliferative Disorders | 1 | 1999 | 91 | 0.140 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 1998 | 107 | 0.140 |
Why?
|
| Neoplasms | 3 | 2007 | 3038 | 0.140 |
Why?
|
| Child | 19 | 2022 | 25890 | 0.140 |
Why?
|
| Tongue Neoplasms | 1 | 2007 | 30 | 0.140 |
Why?
|
| Ribosomal Proteins | 2 | 2008 | 76 | 0.140 |
Why?
|
| DNA Primers | 4 | 2014 | 672 | 0.140 |
Why?
|
| Adenoma | 1 | 1998 | 143 | 0.130 |
Why?
|
| Adolescent | 16 | 2019 | 20624 | 0.130 |
Why?
|
| Genetic Testing | 1 | 2013 | 1099 | 0.130 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2006 | 118 | 0.120 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2013 | 894 | 0.120 |
Why?
|
| Germinoma | 2 | 2000 | 32 | 0.120 |
Why?
|
| Antineoplastic Agents | 3 | 2014 | 1853 | 0.120 |
Why?
|
| Catalytic Domain | 2 | 2015 | 178 | 0.120 |
Why?
|
| Colonic Neoplasms | 2 | 2004 | 272 | 0.120 |
Why?
|
| Neuroblastoma | 1 | 2010 | 550 | 0.110 |
Why?
|
| Complement C1 Inactivator Proteins | 1 | 2004 | 1 | 0.110 |
Why?
|
| Carcinoma, Papillary, Follicular | 1 | 2004 | 2 | 0.110 |
Why?
|
| Casein Kinase II | 1 | 2004 | 15 | 0.110 |
Why?
|
| Cellular Senescence | 1 | 2006 | 201 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 10 | 2 | 2011 | 72 | 0.110 |
Why?
|
| Antibodies, Neoplasm | 1 | 2014 | 60 | 0.110 |
Why?
|
| Esophageal Neoplasms | 3 | 1995 | 396 | 0.110 |
Why?
|
| Thymidylate Synthase | 1 | 2004 | 23 | 0.110 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2015 | 1012 | 0.110 |
Why?
|
| Lasers | 1 | 2004 | 115 | 0.110 |
Why?
|
| Chromosome Inversion | 1 | 1994 | 77 | 0.110 |
Why?
|
| Multienzyme Complexes | 1 | 2004 | 89 | 0.110 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2014 | 96 | 0.110 |
Why?
|
| Aging | 1 | 2011 | 1306 | 0.110 |
Why?
|
| Blotting, Southern | 6 | 2002 | 221 | 0.110 |
Why?
|
| Cysteine Endopeptidases | 1 | 2004 | 119 | 0.110 |
Why?
|
| src-Family Kinases | 1 | 2004 | 97 | 0.110 |
Why?
|
| Osteoblasts | 2 | 2015 | 166 | 0.110 |
Why?
|
| Liver | 1 | 2011 | 1879 | 0.110 |
Why?
|
| DNA Damage | 2 | 2011 | 547 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 1994 | 124 | 0.110 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2013 | 2947 | 0.110 |
Why?
|
| Gene Expression | 4 | 2014 | 1621 | 0.110 |
Why?
|
| Mammary Tumor Virus, Mouse | 1 | 2013 | 108 | 0.110 |
Why?
|
| Colony-Forming Units Assay | 2 | 2014 | 70 | 0.100 |
Why?
|
| Adenosine Triphosphatases | 1 | 2004 | 217 | 0.100 |
Why?
|
| Heterozygote | 3 | 2018 | 728 | 0.100 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2013 | 434 | 0.100 |
Why?
|
| Seminoma | 1 | 2002 | 10 | 0.100 |
Why?
|
| Mice, 129 Strain | 2 | 2014 | 100 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 4 | 2002 | 18 | 0.100 |
Why?
|
| Phosphorylation | 3 | 2014 | 1713 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 15 | 2 | 1999 | 163 | 0.100 |
Why?
|
| Lymphoma, AIDS-Related | 2 | 2009 | 37 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 17 | 4 | 2007 | 374 | 0.100 |
Why?
|
| Expressed Sequence Tags | 1 | 2002 | 83 | 0.100 |
Why?
|
| Cell Nucleus | 2 | 2013 | 691 | 0.100 |
Why?
|
| Mice, Nude | 4 | 2014 | 780 | 0.100 |
Why?
|
| Transcriptional Activation | 1 | 2014 | 504 | 0.100 |
Why?
|
| Child, Preschool | 10 | 2019 | 14884 | 0.100 |
Why?
|
| Neoplasm Grading | 2 | 2013 | 307 | 0.100 |
Why?
|
| Blast Crisis | 1 | 2002 | 18 | 0.100 |
Why?
|
| Lymphocytes | 2 | 2005 | 442 | 0.100 |
Why?
|
| Infant | 9 | 2019 | 13240 | 0.100 |
Why?
|
| Adenocarcinoma, Papillary | 1 | 2002 | 5 | 0.100 |
Why?
|
| Bone Marrow | 2 | 2011 | 336 | 0.100 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2009 | 1317 | 0.100 |
Why?
|
| DNA Probes | 3 | 2005 | 126 | 0.090 |
Why?
|
| Gene Expression Regulation | 3 | 2018 | 2669 | 0.090 |
Why?
|
| Prognosis | 7 | 2015 | 5086 | 0.090 |
Why?
|
| Liver Neoplasms | 2 | 2004 | 1417 | 0.090 |
Why?
|
| Electroporation | 2 | 2013 | 34 | 0.090 |
Why?
|
| RNA, Untranslated | 1 | 2002 | 120 | 0.090 |
Why?
|
| Cell Transformation, Viral | 2 | 2013 | 99 | 0.090 |
Why?
|
| Epithelial Cells | 2 | 2014 | 937 | 0.090 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2002 | 103 | 0.090 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2001 | 88 | 0.090 |
Why?
|
| Hydroxyurea | 1 | 2002 | 87 | 0.090 |
Why?
|
| Receptors, Androgen | 1 | 2014 | 433 | 0.090 |
Why?
|
| Genetic Markers | 5 | 2002 | 635 | 0.090 |
Why?
|
| Thymus Neoplasms | 1 | 2011 | 40 | 0.090 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2013 | 399 | 0.090 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2013 | 616 | 0.090 |
Why?
|
| Doxorubicin | 2 | 2014 | 303 | 0.090 |
Why?
|
| DNA, Complementary | 3 | 2004 | 472 | 0.080 |
Why?
|
| Genome | 1 | 2003 | 528 | 0.080 |
Why?
|
| Neoplasms, Second Primary | 1 | 2002 | 166 | 0.080 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2014 | 703 | 0.080 |
Why?
|
| Oligonucleotides | 1 | 2000 | 93 | 0.080 |
Why?
|
| Principal Component Analysis | 2 | 2015 | 160 | 0.080 |
Why?
|
| Estrogen Receptor alpha | 1 | 2013 | 475 | 0.080 |
Why?
|
| Cell Survival | 3 | 2014 | 890 | 0.080 |
Why?
|
| Cluster Analysis | 2 | 2015 | 440 | 0.080 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2016 | 3506 | 0.080 |
Why?
|
| Up-Regulation | 3 | 2015 | 915 | 0.080 |
Why?
|
| Cell Line | 3 | 2018 | 2864 | 0.080 |
Why?
|
| Cells, Cultured | 4 | 2013 | 3188 | 0.080 |
Why?
|
| Neoplasm Transplantation | 3 | 2014 | 399 | 0.080 |
Why?
|
| Transfection | 3 | 2009 | 1096 | 0.080 |
Why?
|
| Protein Phosphatase 2C | 2 | 2011 | 60 | 0.080 |
Why?
|
| Algorithms | 2 | 2013 | 1736 | 0.080 |
Why?
|
| Immunoglobulins | 2 | 2001 | 175 | 0.080 |
Why?
|
| Neoplasm Staging | 3 | 2014 | 1391 | 0.080 |
Why?
|
| Protein Biosynthesis | 2 | 2008 | 678 | 0.080 |
Why?
|
| Oncogene Protein p55(v-myc) | 1 | 2008 | 4 | 0.080 |
Why?
|
| DNA, Viral | 2 | 2003 | 500 | 0.080 |
Why?
|
| Two-Hybrid System Techniques | 1 | 2008 | 69 | 0.080 |
Why?
|
| Genetic Complementation Test | 1 | 2008 | 90 | 0.080 |
Why?
|
| Anaphase | 1 | 2008 | 13 | 0.080 |
Why?
|
| Colorectal Neoplasms | 1 | 2015 | 652 | 0.070 |
Why?
|
| Amino Acid Sequence | 4 | 2001 | 2795 | 0.070 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 1999 | 64 | 0.070 |
Why?
|
| Immunoprecipitation | 1 | 2008 | 206 | 0.070 |
Why?
|
| Tetracycline | 1 | 2008 | 79 | 0.070 |
Why?
|
| Luminescent Proteins | 1 | 2008 | 166 | 0.070 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 1998 | 90 | 0.070 |
Why?
|
| Telomerase | 2 | 2014 | 179 | 0.070 |
Why?
|
| Hepatoblastoma | 1 | 2000 | 184 | 0.070 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 1998 | 171 | 0.070 |
Why?
|
| Ependymoma | 1 | 2010 | 176 | 0.070 |
Why?
|
| Reproducibility of Results | 4 | 2015 | 3043 | 0.070 |
Why?
|
| Genomic Instability | 2 | 2015 | 248 | 0.070 |
Why?
|
| Down-Regulation | 3 | 2007 | 720 | 0.070 |
Why?
|
| Mice, Knockout | 3 | 2011 | 4016 | 0.070 |
Why?
|
| Glioblastoma | 2 | 2013 | 375 | 0.070 |
Why?
|
| Clone Cells | 3 | 2008 | 180 | 0.070 |
Why?
|
| Mitosis | 2 | 2008 | 205 | 0.070 |
Why?
|
| Proteins | 2 | 2006 | 1101 | 0.070 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 2 | 2002 | 73 | 0.070 |
Why?
|
| Biopsy | 3 | 2016 | 1304 | 0.070 |
Why?
|
| HeLa Cells | 1 | 2008 | 838 | 0.070 |
Why?
|
| Peptide Elongation Factor 1 | 1 | 2006 | 10 | 0.070 |
Why?
|
| Transplantation, Heterologous | 2 | 2014 | 276 | 0.070 |
Why?
|
| Chromosome Disorders | 2 | 2001 | 316 | 0.060 |
Why?
|
| Acute Disease | 3 | 2002 | 1192 | 0.060 |
Why?
|
| Young Adult | 3 | 2018 | 9944 | 0.060 |
Why?
|
| Exons | 5 | 2001 | 839 | 0.060 |
Why?
|
| Cell Division | 2 | 2008 | 774 | 0.060 |
Why?
|
| Transcriptome | 2 | 2014 | 1138 | 0.060 |
Why?
|
| Polymorphism, Restriction Fragment Length | 3 | 2000 | 153 | 0.060 |
Why?
|
| Chromosomes | 2 | 2003 | 164 | 0.060 |
Why?
|
| Phosphoproteins | 1 | 2008 | 459 | 0.060 |
Why?
|
| PAX5 Transcription Factor | 3 | 2002 | 15 | 0.060 |
Why?
|
| Chromosome Breakpoints | 1 | 2015 | 83 | 0.060 |
Why?
|
| Gene Order | 1 | 2015 | 82 | 0.060 |
Why?
|
| Oncogene Proteins | 1 | 2006 | 157 | 0.060 |
Why?
|
| Neoplasm Invasiveness | 2 | 2015 | 675 | 0.060 |
Why?
|
| Caspase 2 | 1 | 2015 | 28 | 0.060 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2015 | 29 | 0.060 |
Why?
|
| RNA | 3 | 2006 | 607 | 0.060 |
Why?
|
| Primary Cell Culture | 1 | 2015 | 110 | 0.060 |
Why?
|
| Simplexvirus | 1 | 1995 | 107 | 0.060 |
Why?
|
| Heterografts | 2 | 2017 | 201 | 0.060 |
Why?
|
| Blotting, Northern | 2 | 2009 | 272 | 0.060 |
Why?
|
| GATA4 Transcription Factor | 1 | 2015 | 43 | 0.060 |
Why?
|
| Protein Structure, Tertiary | 2 | 2014 | 787 | 0.060 |
Why?
|
| Microsatellite Repeats | 2 | 2017 | 241 | 0.060 |
Why?
|
| Indicators and Reagents | 1 | 2005 | 52 | 0.060 |
Why?
|
| Sensitivity and Specificity | 4 | 2004 | 2172 | 0.060 |
Why?
|
| Serum Albumin, Bovine | 1 | 2014 | 56 | 0.060 |
Why?
|
| Signal Transduction | 4 | 2022 | 4934 | 0.060 |
Why?
|
| Protein Binding | 1 | 2008 | 1859 | 0.060 |
Why?
|
| Nucleic Acid Conformation | 1 | 2005 | 198 | 0.060 |
Why?
|
| Mucin-1 | 1 | 2004 | 38 | 0.060 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2014 | 25 | 0.050 |
Why?
|
| Fibrous Dysplasia of Bone | 1 | 2003 | 6 | 0.050 |
Why?
|
| Mice, Inbred Strains | 1 | 2004 | 323 | 0.050 |
Why?
|
| Fibrous Dysplasia, Polyostotic | 1 | 2003 | 7 | 0.050 |
Why?
|
| Interphase | 1 | 1993 | 42 | 0.050 |
Why?
|
| Sarcoma, Kaposi | 1 | 1995 | 137 | 0.050 |
Why?
|
| G2 Phase | 1 | 2003 | 45 | 0.050 |
Why?
|
| Spectroscopy, Fourier Transform Infrared | 1 | 2003 | 39 | 0.050 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2015 | 186 | 0.050 |
Why?
|
| Genetic Loci | 1 | 2015 | 367 | 0.050 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2013 | 806 | 0.050 |
Why?
|
| Gene Rearrangement, B-Lymphocyte, Heavy Chain | 1 | 1993 | 4 | 0.050 |
Why?
|
| Etoposide | 1 | 2014 | 120 | 0.050 |
Why?
|
| Myxoma | 1 | 2003 | 30 | 0.050 |
Why?
|
| Fluorouracil | 1 | 2014 | 141 | 0.050 |
Why?
|
| Retinoblastoma Protein | 1 | 2003 | 86 | 0.050 |
Why?
|
| Cattle | 1 | 2014 | 589 | 0.050 |
Why?
|
| Transcription, Genetic | 3 | 2004 | 1761 | 0.050 |
Why?
|
| Transcriptional Regulator ERG | 1 | 2013 | 42 | 0.050 |
Why?
|
| RNA-Binding Protein EWS | 1 | 2013 | 37 | 0.050 |
Why?
|
| Repressor Proteins | 2 | 2022 | 874 | 0.050 |
Why?
|
| Calcium-Binding Proteins | 1 | 2015 | 337 | 0.050 |
Why?
|
| Carcinoma, Mucoepidermoid | 1 | 2013 | 15 | 0.050 |
Why?
|
| Calmodulin-Binding Proteins | 1 | 2013 | 65 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 22 | 1 | 2013 | 104 | 0.050 |
Why?
|
| B-Lymphocytes | 2 | 2008 | 551 | 0.050 |
Why?
|
| Lymphoma | 2 | 2011 | 336 | 0.050 |
Why?
|
| Cell Death | 1 | 2003 | 252 | 0.050 |
Why?
|
| Disease Models, Animal | 3 | 2015 | 4808 | 0.050 |
Why?
|
| CD3 Complex | 1 | 2013 | 93 | 0.050 |
Why?
|
| Regeneration | 1 | 2015 | 231 | 0.050 |
Why?
|
| Immunoenzyme Techniques | 2 | 2009 | 258 | 0.050 |
Why?
|
| Gene Knockdown Techniques | 1 | 2014 | 399 | 0.050 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2015 | 406 | 0.050 |
Why?
|
| Wheat Germ Agglutinins | 1 | 2012 | 14 | 0.050 |
Why?
|
| Glycogen | 1 | 2012 | 65 | 0.050 |
Why?
|
| Occupational Exposure | 1 | 2003 | 138 | 0.050 |
Why?
|
| Granulosa Cell Tumor | 1 | 1992 | 39 | 0.050 |
Why?
|
| Haploidy | 1 | 2022 | 21 | 0.050 |
Why?
|
| Papillomaviridae | 2 | 2004 | 191 | 0.050 |
Why?
|
| Ribosomes | 1 | 2003 | 141 | 0.050 |
Why?
|
| Genes, src | 1 | 1991 | 4 | 0.050 |
Why?
|
| CREB-Binding Protein | 1 | 2022 | 66 | 0.050 |
Why?
|
| Cell Aggregation | 1 | 2011 | 25 | 0.050 |
Why?
|
| Sex Chromosomes | 1 | 2011 | 33 | 0.050 |
Why?
|
| Hepatic Stellate Cells | 1 | 2011 | 26 | 0.050 |
Why?
|
| Kupffer Cells | 1 | 2011 | 22 | 0.050 |
Why?
|
| DNA Helicases | 1 | 2003 | 254 | 0.050 |
Why?
|
| Diploidy | 2 | 2013 | 39 | 0.050 |
Why?
|
| Hydrolases | 1 | 2011 | 61 | 0.050 |
Why?
|
| Endothelial Cells | 1 | 2015 | 544 | 0.050 |
Why?
|
| Ethanol | 1 | 2002 | 170 | 0.050 |
Why?
|
| Carcinogenesis | 1 | 2014 | 364 | 0.050 |
Why?
|
| Bone Marrow Cells | 1 | 2003 | 275 | 0.040 |
Why?
|
| Cytoskeleton | 1 | 2012 | 175 | 0.040 |
Why?
|
| Gene Transfer Techniques | 1 | 2013 | 365 | 0.040 |
Why?
|
| Wnt Proteins | 1 | 2012 | 226 | 0.040 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2011 | 104 | 0.040 |
Why?
|
| Gene Knockout Techniques | 1 | 2011 | 139 | 0.040 |
Why?
|
| RNA, Neoplasm | 2 | 2014 | 146 | 0.040 |
Why?
|
| Cell Separation | 1 | 2011 | 234 | 0.040 |
Why?
|
| Mice, SCID | 2 | 2014 | 615 | 0.040 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2015 | 628 | 0.040 |
Why?
|
| Kidney Tubules, Proximal | 1 | 1991 | 112 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 2 | 2003 | 92 | 0.040 |
Why?
|
| Mutation, Missense | 1 | 2015 | 947 | 0.040 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2003 | 353 | 0.040 |
Why?
|
| Disease-Free Survival | 2 | 2008 | 972 | 0.040 |
Why?
|
| Spleen | 1 | 2011 | 292 | 0.040 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2003 | 393 | 0.040 |
Why?
|
| Fatal Outcome | 1 | 2011 | 378 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2015 | 964 | 0.040 |
Why?
|
| K562 Cells | 1 | 2010 | 100 | 0.040 |
Why?
|
| Germ Cells | 1 | 2011 | 204 | 0.040 |
Why?
|
| Pyridines | 1 | 2011 | 250 | 0.040 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 1990 | 97 | 0.040 |
Why?
|
| DNA | 2 | 2003 | 1682 | 0.040 |
Why?
|
| Incidence | 2 | 2010 | 3416 | 0.040 |
Why?
|
| Glycoproteins | 1 | 2012 | 381 | 0.040 |
Why?
|
| Myocytes, Cardiac | 1 | 2015 | 676 | 0.040 |
Why?
|
| Genotype | 2 | 2022 | 2814 | 0.040 |
Why?
|
| Cell Line, Transformed | 1 | 2009 | 169 | 0.040 |
Why?
|
| Antigen-Presenting Cells | 1 | 2010 | 133 | 0.040 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 2 | 2000 | 94 | 0.040 |
Why?
|
| Coculture Techniques | 1 | 2010 | 247 | 0.040 |
Why?
|
| Genes, Neurofibromatosis 1 | 1 | 2009 | 3 | 0.040 |
Why?
|
| Acute-Phase Reaction | 1 | 1999 | 14 | 0.040 |
Why?
|
| Serine | 1 | 2010 | 185 | 0.040 |
Why?
|
| Carcinoma, Renal Cell | 1 | 1991 | 253 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 1999 | 59 | 0.040 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2013 | 503 | 0.040 |
Why?
|
| Flow Cytometry | 1 | 2011 | 837 | 0.040 |
Why?
|
| Telomeric Repeat Binding Protein 1 | 1 | 1998 | 3 | 0.040 |
Why?
|
| Pluripotent Stem Cells | 1 | 2009 | 79 | 0.040 |
Why?
|
| Anemia | 1 | 2003 | 349 | 0.040 |
Why?
|
| Plasmids | 1 | 2010 | 529 | 0.040 |
Why?
|
| Transgenes | 1 | 2010 | 346 | 0.040 |
Why?
|
| Cricetulus | 1 | 1998 | 97 | 0.040 |
Why?
|
| CHO Cells | 1 | 1998 | 167 | 0.040 |
Why?
|
| Receptors, Cell Surface | 1 | 2001 | 497 | 0.040 |
Why?
|
| Computational Biology | 1 | 2014 | 890 | 0.040 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2003 | 564 | 0.040 |
Why?
|
| Codon | 1 | 1998 | 109 | 0.040 |
Why?
|
| Blood Donors | 1 | 1998 | 61 | 0.040 |
Why?
|
| Cricetinae | 1 | 1998 | 398 | 0.040 |
Why?
|
| Chondrosarcoma | 1 | 2008 | 14 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 1998 | 65 | 0.040 |
Why?
|
| Chromosomes, Artificial, Yeast | 2 | 1998 | 42 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 21 | 1 | 2008 | 44 | 0.040 |
Why?
|
| Proteomics | 1 | 2012 | 599 | 0.040 |
Why?
|
| Tibia | 1 | 2008 | 83 | 0.030 |
Why?
|
| Alanine | 1 | 1998 | 190 | 0.030 |
Why?
|
| Pharynx | 1 | 2007 | 69 | 0.030 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2007 | 128 | 0.030 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1998 | 673 | 0.030 |
Why?
|
| DNA Copy Number Variations | 1 | 2013 | 1034 | 0.030 |
Why?
|
| NIH 3T3 Cells | 2 | 2008 | 97 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 16 | 1 | 1998 | 150 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2011 | 868 | 0.030 |
Why?
|
| Genomics | 1 | 2015 | 1681 | 0.030 |
Why?
|
| Kidney Neoplasms | 1 | 1991 | 462 | 0.030 |
Why?
|
| Sarcoma | 1 | 2009 | 209 | 0.030 |
Why?
|
| Cisplatin | 1 | 1998 | 287 | 0.030 |
Why?
|
| Survival Analysis | 3 | 2006 | 1599 | 0.030 |
Why?
|
| Caspases | 2 | 2003 | 168 | 0.030 |
Why?
|
| Green Fluorescent Proteins | 1 | 2007 | 402 | 0.030 |
Why?
|
| Genetic Vectors | 1 | 2010 | 970 | 0.030 |
Why?
|
| Proto-Oncogenes | 1 | 1996 | 37 | 0.030 |
Why?
|
| HIV-1 | 1 | 2009 | 488 | 0.030 |
Why?
|
| Cell Movement | 1 | 2009 | 920 | 0.030 |
Why?
|
| Alpha-Amanitin | 1 | 2015 | 1 | 0.030 |
Why?
|
| Epithelial Cell Adhesion Molecule | 1 | 2015 | 5 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2008 | 1146 | 0.030 |
Why?
|
| Genome-Wide Association Study | 1 | 2013 | 1880 | 0.030 |
Why?
|
| Introns | 2 | 2001 | 319 | 0.030 |
Why?
|
| Microdissection | 1 | 2004 | 14 | 0.030 |
Why?
|
| Genetic Therapy | 1 | 2010 | 737 | 0.030 |
Why?
|
| Tumor Protein p73 | 1 | 2004 | 31 | 0.030 |
Why?
|
| Immunoconjugates | 1 | 2015 | 46 | 0.030 |
Why?
|
| RNA Polymerase II | 1 | 2015 | 102 | 0.030 |
Why?
|
| Complement C1 Inhibitor Protein | 1 | 2004 | 8 | 0.030 |
Why?
|
| Culture Media, Serum-Free | 1 | 2014 | 23 | 0.030 |
Why?
|
| Pregnancy | 2 | 2013 | 7570 | 0.030 |
Why?
|
| Ki-67 Antigen | 1 | 2004 | 119 | 0.030 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 2004 | 41 | 0.030 |
Why?
|
| Alleles | 2 | 2000 | 1724 | 0.030 |
Why?
|
| E2F Transcription Factors | 1 | 2004 | 27 | 0.030 |
Why?
|
| Prostatic Neoplasms | 1 | 2003 | 1626 | 0.030 |
Why?
|
| Embryo, Mammalian | 1 | 2006 | 467 | 0.030 |
Why?
|
| Postmenopause | 1 | 2004 | 155 | 0.030 |
Why?
|
| E2F1 Transcription Factor | 1 | 2004 | 51 | 0.030 |
Why?
|
| Cell Adhesion Molecules | 1 | 2015 | 256 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2011 | 1356 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2014 | 259 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2007 | 1310 | 0.030 |
Why?
|
| Antibodies | 1 | 2015 | 382 | 0.030 |
Why?
|
| Protein Transport | 1 | 2014 | 390 | 0.030 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 1998 | 560 | 0.030 |
Why?
|
| Artificial Gene Fusion | 1 | 2002 | 12 | 0.030 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2004 | 278 | 0.030 |
Why?
|
| Embryonic Stem Cells | 1 | 2013 | 178 | 0.020 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2002 | 90 | 0.020 |
Why?
|
| Protein Array Analysis | 1 | 2003 | 107 | 0.020 |
Why?
|
| Antigens, Neoplasm | 1 | 2015 | 408 | 0.020 |
Why?
|
| Databases, Genetic | 1 | 2015 | 507 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2002 | 59 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2008 | 1979 | 0.020 |
Why?
|
| Philadelphia Chromosome | 1 | 2002 | 43 | 0.020 |
Why?
|
| Exome | 1 | 2017 | 1087 | 0.020 |
Why?
|
| Alternative Splicing | 1 | 2014 | 378 | 0.020 |
Why?
|
| Polyadenylation | 1 | 2002 | 56 | 0.020 |
Why?
|
| Demecolcine | 1 | 2001 | 3 | 0.020 |
Why?
|
| Cytogenetics | 1 | 2001 | 18 | 0.020 |
Why?
|
| Biomarkers | 1 | 2011 | 3434 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2008 | 13074 | 0.020 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2002 | 111 | 0.020 |
Why?
|
| Paclitaxel | 1 | 2002 | 143 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2004 | 827 | 0.020 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2002 | 109 | 0.020 |
Why?
|
| Models, Theoretical | 1 | 2013 | 398 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 2 | 2000 | 1837 | 0.020 |
Why?
|
| Gene Conversion | 1 | 2000 | 15 | 0.020 |
Why?
|
| Apoptotic Protease-Activating Factor 1 | 1 | 2000 | 12 | 0.020 |
Why?
|
| Physical Chromosome Mapping | 1 | 2000 | 57 | 0.020 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2002 | 262 | 0.020 |
Why?
|
| Linear Models | 1 | 2002 | 723 | 0.020 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 2000 | 295 | 0.020 |
Why?
|
| Hydrolysis | 1 | 2000 | 164 | 0.020 |
Why?
|
| Caspase 3 | 1 | 2000 | 141 | 0.020 |
Why?
|
| Monosomy | 1 | 2000 | 25 | 0.020 |
Why?
|
| Lymph Nodes | 1 | 2002 | 399 | 0.020 |
Why?
|
| Genes, DCC | 1 | 1999 | 1 | 0.020 |
Why?
|
| Genes, bcl-2 | 1 | 1999 | 9 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2002 | 512 | 0.020 |
Why?
|
| Survival Rate | 1 | 2004 | 2218 | 0.020 |
Why?
|
| Cytokinesis | 1 | 2008 | 26 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2004 | 2301 | 0.020 |
Why?
|
| Sequence Tagged Sites | 1 | 1998 | 27 | 0.020 |
Why?
|
| Cell Size | 1 | 2008 | 90 | 0.020 |
Why?
|
| Genes, cdc | 1 | 2008 | 25 | 0.020 |
Why?
|
| Molecular Probe Techniques | 1 | 1998 | 23 | 0.020 |
Why?
|
| Myosins | 1 | 1998 | 47 | 0.020 |
Why?
|
| Minisatellite Repeats | 1 | 1998 | 45 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 1998 | 67 | 0.020 |
Why?
|
| Kruppel-Like Factor 6 | 1 | 1997 | 1 | 0.020 |
Why?
|
| Genes, Immunoglobulin | 1 | 1997 | 33 | 0.020 |
Why?
|
| Hybrid Cells | 1 | 1997 | 79 | 0.020 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 1997 | 50 | 0.020 |
Why?
|
| Genomic Library | 1 | 1997 | 42 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2002 | 1250 | 0.020 |
Why?
|
| Restriction Mapping | 1 | 1997 | 193 | 0.020 |
Why?
|
| Models, Genetic | 1 | 2000 | 789 | 0.020 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 1997 | 120 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2008 | 3857 | 0.020 |
Why?
|
| Genes, Neoplasm | 1 | 2006 | 91 | 0.020 |
Why?
|
| Placenta | 1 | 2000 | 536 | 0.020 |
Why?
|
| Receptors, IgE | 1 | 1995 | 11 | 0.020 |
Why?
|
| DNA Restriction Enzymes | 1 | 1995 | 122 | 0.020 |
Why?
|
| Sequence Homology | 1 | 1995 | 64 | 0.020 |
Why?
|
| Precancerous Conditions | 1 | 2008 | 288 | 0.020 |
Why?
|
| Hedgehog Proteins | 1 | 2006 | 268 | 0.010 |
Why?
|
| Testis | 1 | 1997 | 433 | 0.010 |
Why?
|
| Otorhinolaryngologic Neoplasms | 1 | 1994 | 3 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2004 | 5477 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 1995 | 485 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2004 | 5222 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 1995 | 344 | 0.010 |
Why?
|
| Cytoplasm | 1 | 1995 | 304 | 0.010 |
Why?
|
| Chromosomes, Artificial, Bacterial | 1 | 2004 | 94 | 0.010 |
Why?
|
| Monte Carlo Method | 1 | 2004 | 102 | 0.010 |
Why?
|
| RNA, Small Interfering | 1 | 2006 | 721 | 0.010 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2004 | 72 | 0.010 |
Why?
|
| Ploidies | 1 | 1993 | 38 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2006 | 1089 | 0.010 |
Why?
|
| Caspase 10 | 1 | 2003 | 3 | 0.010 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2006 | 596 | 0.010 |
Why?
|
| Ku Autoantigen | 1 | 2003 | 22 | 0.010 |
Why?
|
| Mouth Neoplasms | 1 | 1994 | 115 | 0.010 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2003 | 121 | 0.010 |
Why?
|
| Antigens, Nuclear | 1 | 2003 | 57 | 0.010 |
Why?
|
| Oncogene Protein pp60(v-src) | 1 | 1991 | 2 | 0.010 |
Why?
|
| Time Factors | 1 | 2002 | 6610 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 1991 | 158 | 0.010 |
Why?
|
| DNA Fingerprinting | 1 | 2001 | 111 | 0.010 |
Why?
|
| Myeloma Proteins | 1 | 2001 | 4 | 0.010 |
Why?
|
| Retroviridae | 1 | 1991 | 198 | 0.010 |
Why?
|
| Receptors, Fc | 1 | 2001 | 33 | 0.010 |
Why?
|
| Rats | 1 | 1997 | 3890 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2004 | 1488 | 0.010 |
Why?
|
| Multigene Family | 1 | 2001 | 324 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2002 | 8623 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2007 | 17540 | 0.010 |
Why?
|
| Germ-Line Mutation | 1 | 2001 | 370 | 0.010 |
Why?
|
| GC Rich Sequence | 1 | 1998 | 6 | 0.010 |
Why?
|
| Alu Elements | 1 | 1998 | 67 | 0.010 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1998 | 373 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-rel | 1 | 1996 | 3 | 0.010 |
Why?
|
| Organ Specificity | 1 | 1996 | 443 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 1990 | 1072 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 1998 | 1433 | 0.010 |
Why?
|